A detailed history of Ingalls & Snyder LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ingalls & Snyder LLC holds 12,700 shares of BMY stock, worth $733,552. This represents 0.03% of its overall portfolio holdings.

Number of Shares
12,700
Previous 12,700 -0.0%
Holding current value
$733,552
Previous $527,000 24.67%
% of portfolio
0.03%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$39.66 - $51.75 $1.25 Million - $1.63 Million
-31,505 Reduced 16.3%
161,831 $8.37 Million
Q2 2024

Jul 31, 2024

SELL
$40.25 - $52.99 $11.1 Million - $14.6 Million
-274,803 Reduced 58.7%
193,336 $8.03 Million
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $1.73 Million - $1.96 Million
36,072 Added 8.35%
468,139 $25.4 Million
Q4 2023

Jan 29, 2024

SELL
$48.48 - $57.85 $2.52 Million - $3 Million
-51,879 Reduced 10.72%
432,067 $22.2 Million
Q3 2023

Nov 02, 2023

SELL
$57.89 - $64.73 $295,528 - $330,446
-5,105 Reduced 1.04%
483,946 $28.1 Million
Q2 2023

Jul 27, 2023

BUY
$63.71 - $70.74 $662,456 - $735,554
10,398 Added 2.17%
489,051 $31.3 Million
Q1 2023

May 09, 2023

BUY
$65.71 - $74.53 $1.12 Million - $1.27 Million
17,032 Added 3.69%
478,653 $33.2 Million
Q4 2022

Jan 31, 2023

SELL
$68.48 - $81.09 $648,779 - $768,246
-9,474 Reduced 2.01%
461,621 $33.2 Million
Q3 2022

Oct 21, 2022

SELL
$0.13 - $76.84 $230 - $136,237
-1,773 Reduced 0.37%
471,095 $33.5 Million
Q2 2022

Aug 11, 2022

SELL
$72.62 - $79.98 $219,602 - $241,859
-3,024 Reduced 0.64%
472,868 $36.4 Million
Q1 2022

May 09, 2022

BUY
$61.48 - $73.72 $149,765 - $179,581
2,436 Added 0.51%
475,892 $34.8 Million
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $991,994 - $1.16 Million
-18,497 Reduced 3.76%
473,456 $29.5 Million
Q3 2021

Oct 27, 2021

SELL
$59.17 - $69.31 $672,407 - $787,638
-11,364 Reduced 2.26%
491,953 $29.1 Million
Q2 2021

Aug 03, 2021

BUY
$61.91 - $67.42 $66,243 - $72,139
1,070 Added 0.21%
503,317 $33.6 Million
Q1 2021

Apr 21, 2021

SELL
$59.34 - $66.74 $600,758 - $675,675
-10,124 Reduced 1.98%
502,247 $31.7 Million
Q4 2020

Jan 27, 2021

BUY
$57.74 - $65.43 $29.6 Million - $33.5 Million
512,371 New
512,371 $31.8 Million
Q3 2020

Oct 21, 2020

SELL
$57.43 - $63.64 $29.3 Million - $32.4 Million
-509,601 Closed
0 $0
Q2 2020

Jul 31, 2020

BUY
$54.82 - $64.09 $76,090 - $88,956
1,388 Added 0.27%
509,601 $30 Million
Q1 2020

Apr 22, 2020

BUY
$46.4 - $67.43 $520,515 - $756,429
11,218 Added 2.26%
508,213 $28.3 Million
Q4 2019

Jan 15, 2020

BUY
$49.21 - $64.19 $5.03 Million - $6.56 Million
102,242 Added 25.9%
496,995 $31.9 Million
Q3 2019

Oct 16, 2019

SELL
$42.77 - $50.71 $491,170 - $582,353
-11,484 Reduced 2.83%
394,753 $20 Million
Q2 2019

Jul 11, 2019

BUY
$44.62 - $49.34 $9.19 Million - $10.2 Million
206,048 Added 102.93%
406,237 $18.4 Million
Q1 2019

Apr 11, 2019

BUY
$45.12 - $53.8 $451,019 - $537,784
9,996 Added 5.26%
200,189 $9.55 Million
Q4 2018

Jan 24, 2019

SELL
$48.76 - $63.23 $360,531 - $467,522
-7,394 Reduced 3.74%
190,193 $9.89 Million
Q3 2018

Oct 24, 2018

SELL
$55.19 - $62.25 $41,006 - $46,251
-743 Reduced 0.37%
197,587 $12.3 Million
Q2 2018

Aug 10, 2018

SELL
$50.53 - $62.98 $16,270 - $20,279
-322 Reduced 0.16%
198,330 $11 Million
Q1 2018

Apr 17, 2018

BUY
$59.92 - $68.98 $184,613 - $212,527
3,081 Added 1.58%
198,652 $12.6 Million
Q4 2017

Jan 19, 2018

BUY
$59.94 - $65.35 $13,486 - $14,703
225 Added 0.12%
195,571 $12 Million
Q3 2017

Oct 20, 2017

BUY
$55.23 - $63.74 $10.8 Million - $12.5 Million
195,346
195,346 $12.5 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Ingalls & Snyder LLC Portfolio

Follow Ingalls & Snyder LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ingalls & Snyder LLC with notifications on news.